Daxor (DXR) Corporation announces the submission of its next-generation blood volume analyzer – Daxor BVA – to the Food and Drug Administration, advancing its mission to optimize healthcare through precise fluid management. The new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume. Unlike its predecessor, the Daxor BVA-100 system, this innovative analyzer is engineered to be: Three times faster in processing; Significantly simpler to operate; Completely portable; Allows for point of care analysis
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor announces new data from Duke University on BVA at ACC
- Daxor expands blood volume analysis technology across three networks
- Daxor Corporation Reports Robust Growth in Earnings Call
- Daxor’s Promising Growth Trajectory and Strategic Positioning Justifies Buy Rating
- Daxor Corporation Reports Strong 2024 Financial Growth